Basic HTML Version
51
october 7-9, 2012 • NEW ORLEANS, LA
with either the mutation FLT3-ITD or the surface expression
of CD7.
Conclusions:
Mutation FLT3-ITD associates with
the CD7 expression and both can be considered as the
markers of poor prognosis in the overall survival in patients
with AML.Competing interests: The authors declare that they
have no competing interests.
P38
THE FREQUENCY OF LEUKEMIA-ASSOCIATED
PHENOTYPE (LAP) IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA.
Konstantin Slobodnyuk, Margarita Ivanchenko, Margarita
Gorchakova, Maria Estrina, Ekaterina Rusanova, Yekaterina
Zueva
State Pavlov Medical University
Background:
The immunophenotyping is of paramount
importance for the detection of the independent prognostic
factors in acute myeloid leukemia (AML). The aim of
our study was to determine the frequency of different
immunophenotypes in patients with AML.
Methods:
Bone
marrow (BM; n=45) samples from patients with acute
myeloid leukemia, and BM samples from 13 healthy donors,
were stained with a five-color uorescent monoclonal
antibody (MAb) cocktails. We used following MAb panel
with CD45 ECD combined in each tube with FITC, PE,
PC5, and PC7 conjugated MAbs: CD5/CD10/CD34/CD19,
CD15/CD33/CD34/CD117, CD34/CD33/CD7/CD117, CD14/
CD13/HLA-DR/CD184, CD64/CD11b/CD16/CD2, CD36/
CD71/CD33/CD61, CD4/CD8/CD3/CD56, CD22/CD133/
CD25/ CD20. For the detection of blast cells we used gating
strategy CD45/SS. The data was acquired on BC FC500
cytometer and analyzed by CXP Analysis software ™.
Results:
We detected LAP in 41 of 45 cases (91%). Two
or more LAP types were detected in 37 patients (83%). The
asynchronous antigen expression was the most frequent
type of abnormal phenotype profile of cells whereas the
cross-lineage antigen expression was the less one (14
cases, 31%). The absence of the CD13 antigen expression
was prevalent among myeloid antigens, and the most
commonplace cross-lineage antigen was CD7.
Conclusions:
The presented results demonstrate that leukemia-associated
immunophenotype can be detected virtually in all cases
(91%) prior to the diagnosis of acute myeloid leukemia. The
most frequent type of abnormal phenotype is asynchronous
antigen expression. Competing interests: The authors
declare that they have no competing interests.
P39
QUANTIFICATION OF EXPRESSION OF ANTIGENS
TARGETED BY ANTIBODY BASED THERAPY IN
CHRONIC LYMPHOCYTIC LEUKEMIA
Prashant R Tembhare
1
, Gerald Marti
2
, Adrian Wiestner
3
,
Heba Degheidy
2
, Mohammed Farooqui
3
, Robert J
Kreitman4, Gregory A Jasper1, Constance M Yuan1, David
Liewehr
5
, David Venzon
5
, Maryalice Stetler-Stevenson
1
1
Flow Cytometry Unit, Laboratory of Pathology Center for
Cancer Research, NCI, NIH,
2
Center for Biologics Evaluation
and Research, FDA,
3
NHLBI, NIH,
4
Laboratory of Molecular
Biology Center for Cancer Research, NCI, NIH,
5
Biostatistics
and Data Management Section, Center for Cancer
Research, NCI, NIH
Introduction:
Chronic lymphocytic leukemia (CLL) is
an indolent chronic lymphoproliferative disorder, with
the majority of patients eventually requiring therapeutic
intervention. Anti-CD20 (Rituximab), ant-CD52
(Alemtuzumab), anti-CD22 (BL22, HA22) and anti-CD25
(Oncotac) are mainstay therapeutic options or pre-clinical
options under development for the treatment of CLL.
POSTER ABSTRACTS